- Sirona Biochem (SBM) and Wanbang Biopharmaceuticals have signed an expanded international partnership agreement on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment, adding human health in addition to animals
- Sirona has been working to advance TFC-039 as a treatment for diabetes and chronic kidney disease in companion animals
- SGLT2 inhibitors can treat inflicted animals with oral medication as opposed to the traditional method of daily insulin injections
- Sirona Biochem (SBM) is down 6.90 per cent, trading at $0.135 per share as of 09:55 am ET
Sirona Biochem (SBM) will collaborate with Wanbang Biopharmaceuticals on its treatment for animal and human health.
The two companies have signed an expanded, international partnership agreement on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment, adding human health to the because of new licencing opportunities.
Together, Sirona and Wanbang share knowledge and scientific results of TFC-039. The shared data spans more than 12 years of research and development and includes in vitro and in vivo preclinical work, multiple clinical studies, advanced manufacturing process development and the ability to commercially manufacture TFC-039.
Sirona has been working to advance TFC-039 as a treatment for diabetes and chronic kidney disease in companion animals. SGLT2 inhibitors can treat inflicted animals with oral medication as opposed to the traditional method of daily insulin injections.
The company’s CEO, Dr. Howard Verrico, said that Wanbang has invested millions of dollars into the clinical stage research and development of the manufacturing processes for TFC-039.
“These pieces of data are critical to large organizations and will greatly increase the opportunities to move forward. The probability of a successful licensing agreement has been made much stronger by leveraging our alliance with Wanbang. We have had a successful year building Sirona’s pipeline, with positive movement on all projects and we’re looking forward to continuing this success with our SGLT2 inhibitor as well as our antiviral and anti-aging projects in 2023.”
Sirona Biochem is a cosmetic ingredient and drug discovery company specializing in stabilizing carbohydrate molecules to improve efficacy and safety. Its compounds are licensed to leading companies around the world.
Sirona Biochem (SBM) is down 6.90 per cent, trading at $0.135 per share as of 09:55 am ET.
